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ABSTRACT
Background: To date, the relationship between zolpidem use and subsequent risk of glaucoma in a Taiwanese
population has not been assessed.
Methods: We used data from the National Health Insurance system to investigate whether zolpidem use was related
to glaucoma risk. A 1:4 matched case-control study was conducted. The cases were patients newly diagnosed with
glaucoma from 2001 to 2010. The controls were randomly selected non-glaucoma subjects matched by sex and age
(±5 years). Zolpidem exposure and/or the average dosage of zolpidem used (mg/year) were evaluated. Medical
comorbidities were considered as confounding factors. Multiple logistic regression models were used to evaluate the
potential risk of zolpidem exposure on glaucoma with/without adjustment for the effects of confounding variables.
Results: The exposure rate of zolpidem use in the glaucoma group was signiﬁcantly higher than that of the control
group (2.8% vs. 2.0%, P < 0.0001). The adjusted odds ratio (OR) of the risk of glaucoma for those with zolpidem use
vs. those without was 1.19 (95% conﬁdence interval [CI], 1.02–1.38). Compared to non-zolpidem users, zolpidem
users with an average dose of more than 200mg/year had signiﬁcantly increased risk of glaucoma (OR 1.31, 95% CI
1.03–1.68).
Conclusions: This study suggests that the use of zolpidem might increase the risk of subsequent glaucoma. Further
conﬁrmatory studies are recommended to clarify this important issue.
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INTRODUCTION
Insomnia is a quite common and distressing problem in the
general population. Researchers used to deﬁne insomnia as
prolonged sleep latency, reduced sleep efﬁciency, or more
than 3 episodes of sleep disturbance per week.1 Glaucoma
is the main cause of blindness,2 and systemic ﬁndings in
glaucoma patients include alterations of the cardiovascular
system, autonomic nervous system, and immune system,
as well as endocrinological, psychological, and sleep
disturbances.3 One study demonstrated a self-reported
prolonged sleep-onset latency in normal-tension glaucoma
(NTG) patients with vascular dysregulation.4 However, the
association between glaucoma and insomnia has been well
noted but not extensively studied to date.
Zolpidem is a non-benzodiazepine hypnotic drug that
enhances GABA(A) receptor function by interaction with
the Omega-1 receptor subtype.5 It has rapid onset of action,
improves total sleep duration, and reduces incidence of night-
time awakenings.5 Zolpidem is the most commonly prescribed
hypnotic agent worldwide and remains the market leader in
Taiwan.6 Therefore, even a minor hazard could have important
clinical implications.6
To our knowledge, no published reports have addressed the
relationship between zolpidem use and the risk of glaucoma.
Here, we gather information and data from Taiwan’s National
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Health Insurance Research Database (NHIRD) to help us
clarify this important issue.
MATERIALS AND METHODS
Data source
The Taiwanese government organized the Taiwan health
insurance program, which has provided universal and single-
payer insurance since 1996 and involves approximately 99%
of the 23 million Taiwanese. The National Health Research
Institutes (NHRI) established the NHIRD, which contained
the annual original claim data for reimbursement. Before
NHIRD data was released for research, all personal
identiﬁcation information was encoded to guard patient
privacy. This study was approved by the Institutional
Review Board of the China Medical University Hospital
(CMU-REC-101-012).
The data of the study was collected from the Longitudinal
Health Insurance Database (LHID), which is a part of the
NHIRD. The LHID contains 1 million insured individuals
randomly selected from the NHIRD insured individuals
during the period of 1996–2000. According to the NHRI
report, there were no differences in age and sex distribution
between the NHIRD and LHID. The LHID provided each
individual’s information, including sex, birth date, and
registry of medical services, and combined these data using
a scrambled, anonymous identiﬁcation number.
Diseases were recorded in the NHIRD using the
International Classiﬁcation of Diseases, Ninth Revision,
Clinical Modiﬁcation (ICD-9-CM). In this study, the disease
history and drug usage information were collected from
inpatient and outpatient ﬁles.
Study population
This study was a population-based case-control study design.
The case group comprised patients newly diagnosed with
glaucoma (ICD-9-CM 365) from 2001 to 2010 and set the
index date as the date of glaucoma diagnosis. The control
group comprised individuals without glaucoma in LHID who
were randomly frequency matched at 1:4 ratios by age (in
strata of 5 years) and sex. The index date of the control group
was a randomly assigned day and month with the same
index year as the case group. Both study groups excluded
individuals who were prescribed benzodiazepines before the
index date.
The risk exposure of interest was zolpidem use. The study
also measured the average dose of zolpidem (mg/years),
which was deﬁned as the total amount of zolpidem used
before the index date divided by the number of years from
initial zolpidem use to the index date. Not only demographic
factors but also comorbidities were considered as confounding
factors. The comorbidities included diabetes (ICD-9-CM
250), coronary artery disease (CAD; ICD-9-CM 410–414),
hypertension (ICD-9-CM 401–405), hyperlipidemia (ICD-9-
CM 272), anxiety (ICD-9-CM 300.0, 300.2, 300.3, 308.3 and
309.81), and depression (ICD-9-CM 296.2, 296.3, 300.4 and
311) before the index date.
Statistical analysis
We calculated means and standard deviation (SD) for age
and number and proportion for sex, zolpidem use, and
comorbidities to describe the distribution of study groups.
To test the differences between these two groups, we used
the t-test for continuous variable and the chi-square test for
categorical variables. The odds ratios (ORs) with 95%
conﬁdence intervals (CIs) were estimated to examine the
potential risk factors’ effect on glaucoma by using the multiple
logistic regression method. To understand if the impact of
zolpidem use on the risk of glaucoma was moderated by
comorbidities, we used the multiple logistic regression method
with interaction terms incorporated into the model.
The data management and statistical analysis were
performed by SAS 9.3 (SAS Institute, Cary, NC, USA). The
statistical signiﬁcance was deﬁned as (two-sided) P-value
<0.05.
RESULTS
There were 8898 glaucoma patients in the case group and
35 592 subjects in the control group. Due to the 1:4 matched-
case-control design (by age and sex), as shown in Table 1,
subjects in both groups had the same mean age (40.5 years)
Table 1. Demographic status and comorbidities of the
control group and glaucoma group
Variable
Control group
n = 35592 (%)
Glaucoma group
n = 8898 (%)
P-value
Age, years (SD)a 40.5 (20.5) 40.5 (20.5) 0.8243
<45 20396 (57.3) 5099 (57.3) >0.99
45–65 10096 (28.4) 2524 (28.4)
≥65 5100 (14.3) 1275 (14.3)
Sex >0.99
Female 15248 (42.8) 3812 (42.8)
Male 20344 (57.2) 5086 (57.2)
Zolpidem exposure
No 34892 (98.0) 8646 (97.2) <0.0001
Yes 700 (2.0) 252 (2.8)
Zolpidem average
exposure, mg/year
No 34892 (98.0) 8646 (97.2) <0.0001
<40 264 (0.7) 81 (0.9)
40–199 203 (0.6) 73 (0.8)
≥200 233 (0.7) 98 (1.1)
Comorbidity
Hypertension 4491 (12.6) 1622 (18.2) <0.0001
Diabetes 1754 (4.9) 995 (11.2) <0.0001
CAD 1337 (3.8) 486 (5.5) <0.0001
Hyperlipidemia 2672 (7.5) 1176 (13.2) <0.0001
Depression 110 (0.3) 30 (0.3) 0.6721
Anxiety 224 (0.6) 97 (1.1) <0.0001
CAD, coronary artery disease; SD, standard deviation.
at-test.
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and sex ratio (57.2% male). The exposure rate of zolpidem use
in the glaucoma group was signiﬁcantly higher than in the
control group (2.8% vs. 2.0%, P < 0.0001). The occurrence
rates of comorbidities, namely hypertension, diabetes, CAD,
hyperlipidemia, and anxiety, in the glaucoma group were
signiﬁcantly higher than in the control group (all P < 0.0001,
except depression).
After adjusted for hypertension, diabetes, CAD,
hyperlipidemia, depression, and anxiety, individuals with
zolpidem use had a 1.19-fold increased risk of glaucoma
compared to those without zolpidem use (OR 1.19, 95% CI
1.02–1.38; Table 2). Compared to individuals without
zolpidem use, the risk of glaucoma was signiﬁcantly
increased in individuals receiving the highest average dose
(≥200mg/year), with an OR of 1.31 (95% CI 1.03–1.68). The
results also revealed an increasing trend of glaucoma risk with
increasing average dose of zolpidem use (P-trend = 0.01).
Table 3 demonstrates the interaction effects between
zolpidem use and comorbidities on the risk of glaucoma.
These results demonstrated that only diabetes had interaction
for risk of glaucoma with zolpidem use (P = 0.025).
DISCUSSION
In the present study, we assessed the association between the
use of zolpidem and increased risk of glaucoma using a
population-based case-control study design. Regarding the
effect of zolpidem dosage on the onset of glaucoma, we used
zolpidem dosage/per year to evaluate both the total amount of
zolpidem used as well as the exposure period. We found that
zolpidem dosage was positively correlated to glaucoma risk
(P-trend < 0.0001). Two potential reasons for this result may
be considered: an indirect or direct relationship between
zolpidem use and risk of glaucoma.
As far as we know, zolpidem is primarily effective in
inducing sleep with minimal effect on sleep duration or sleep
maintenance.7 The problem of sleep disturbance in glaucoma
has been noted previously.3,4 It was proposed that glaucoma
patients might have difﬁculties preparing physiologically for
sleep due to an impaired ability to initiate distal vasodilation.8
In one study, they found that the NTG patients revealed a
prolonged sleep-onset latency both in the evening as well as
after nocturnal sleep interruption when rated with a sleep
questionnaire.4 Flammer et al. reported that glaucoma patients
with vasospastic syndrome often suffer from cold hands and
cold feet and respond to cold stimuli or even emotional stress
with inappropriate constriction or insufﬁcient dilation in the
microcirculation.9 Systemic vascular dysregulation has been
well-noted in glaucoma patients.10,11 A possible explanation
for the strong association of zolpidem use and glaucoma
might be due to this vascular dysregulation in insomnia
patients, which is supported by results of our study.
Table 2. Odds ratiosa for glaucoma in individual with
zolpidem exposure relative to those without
zolpidem exposure
Variable
Crude Odds
Ratio
(95% CI)
Adjusted Odds
Ratio
(95% CI)
Zolpidem exposure
No ref ref
Yes 1.45 (1.26–1.68) 1.19 (1.02–1.38)
Zolpidem average exposure
(mg/year)
No ref ref
<40 1.24 (0.96–1.59) 1.06 (0.83–1.37)
40–199 1.45 (1.11–1.90) 1.19 (0.91–1.57)
≥200 1.70 (1.34–2.15) 1.31 (1.03–1.68)
P-trend < 0.0001 P-trend = 0.0120
Hypertension 1.54 (1.45–1.64) 1.16 (1.08–1.25)
Diabetes 2.43 (2.24–2.64) 1.95 (1.77–2.14)
CAD 1.48 (1.33–1.65) 0.98 (0.87–1.10)
Hyperlipidemia 1.88 (1.74–2.02) 1.35 (1.24–1.48)
Depression 1.09 (0.73–1.64) 0.77 (0.51–1.18)
Anxiety 1.74 (1.37–2.21) 1.48 (1.16–1.90)
CAD, coronary artery disease; CI, conﬁdence interval.
aModel was adjusted for hypertension, diabetes, CAD, hyperlipidemia,
depression, and anxiety.
Table 3. Interaction between zolpidem exposure and
comorbidities associated with glaucoma risk
Variable OR (95% CI) P-valuea
Zolpidem exposure Hypertension 0.085
No No ref
No Yes 1.54 (1.45–1.65)
Yes No 1.45 (1.20–1.75)
Yes Yes 1.72 (1.37–2.16)
Zolpidem exposure Diabetes 0.025
No No ref
No Yes 2.46 (2.26–2.67)
Yes No 1.41 (1.20–1.67)
Yes Yes 2.29 (1.67–3.15)
Zolpidem exposure CAD 0.391
No No ref
No Yes 1.47 (1.32–1.64)
Yes No 1.43 (1.22–1.68)
Yes Yes 1.76 (1.23–2.53)
Zolpidem exposure Hyperlipidemia 0.101
No No ref
No Yes 1.88 (1.74–2.03)
Yes No 1.40 (1.18–1.67)
Yes Yes 2.00 (1.53–2.63)
Zolpidem exposure Anxiety 0.134
No No ref
No Yes 1.79 (1.36–2.35)
Yes No 1.44 (1.24–1.68)
Yes Yes 1.65 (1.01–2.71)
Zolpidem exposure Depression 0.219
No No ref
No Yes 1.16 (0.73–1.85)
Yes No 1.48 (1.27–1.71)
Yes Yes 0.94 (0.41–2.15)
CAD, coronary artery disease; CI, conﬁdence interval; OR, odds ratio.
aP-value for interaction.
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Another potential direct explanation for the strong
association between glaucoma and zolpidem usage is the
effect of the drug itself. Zolpidem is mainly metabolized
by cytochrome P450 enzymes of the liver, and drug
bioavailability can be determined from blood and urine
samples.12 The possible vascular side effects of zolpidem have
been reported in the literature. A large population-based case-
control study from Taiwan found that zolpidem exposure was
associated with increased risk of ischemic stroke.6 Vascular
headache associated with hallucination was also noted as
an adverse effects of Zolpidem.13 In one double-blind and
placebo-controlled study assessing zolpidem’s effects within
the brain, the dose-related effect of zolpidem in the visual
cortex was clariﬁed.14 The signal of blood oxygen level-
dependent functional magnetic resonance imaging (BOLD
fMRI) was signiﬁcantly reduced at elevated dosages of
zolpidem.14 To our knowledge, glaucomatous damage is a
slowly progressive neuronal degenerative process along the
visual pathway.15–17 Decreased cerebral and ocular blood ﬂow
as well as impaired vascular autoregulation have been
identiﬁed in glaucoma patients.15 Furthermore, visual cortex
involvement in glaucoma patients has also been well
studied.16,17 Given these ﬁndings, it seems that, for some
patients, glaucomatous damage may be not only an ocular
manifestation but also indicative of a more widespread
vascular abnormality involving the brain.15 To identify the
direct inﬂuence of zolpidem use and risk of glaucoma based
on the current results and established theories, further study
should be designed to clarify the effect of zolpidem on ocular
or cerebral blood ﬂow in the near future.
Another interesting result obtained from the current work is
that only diabetes had interaction for risk of glaucoma with
zolpidem use (P-interaction = 0.025) but not hypertension,
hyperlipidemia, or CAD. Several large-scale epidemiologic
studies have tried to elucidate the role of metabolic syndrome
in glaucoma. In one recent study,18 the authors report that
those with diabetes (hazard ratio [HR] 1.35, 95% CI
1.21–1.50) or hypertension (HR 1.17, 95% CI 1.13–1.22)
alone or in combination (HR 1.48, 95% CI 1.39–1.58) had an
increased hazard of developing open-angle glaucoma (OAG)
relative to persons without these conditions. In contrast, those
with hyperlipidemia alone had a 5% decreased hazard of OAG
(HR 0.95, 95% CI 0.91–0.98). We believe different study
designs in other ethnic groups might have different ﬁndings.
Further prospective and longitudinal observational studies are
needed to clarify this important issue.
In the face of increasing usage of zolpidem and increasingly
reported side effects worldwide, Taiwan’s healthcare com-
munity has implemented a strict monitoring system for
zolpidem prescription, which creates a virtual private
network to remind clinicians of the amount of zolpidem
prescribed to each patient over the past 3 months on each
visit.19 Taiwan residents may also access the Taiwan
Consumer Drug Safety platform to read drug safety
information for each drug.20 All of these policies aim to
regulate the usage of hypnotics to prevent drug abuse and
related side effects.
We believe that our work has some strengths. The database
used is an accurate representative sample population of
Taiwanese, and our sample randomization was successful.
Furthermore, this dataset captures data on a broad range of
subjects of different sociodemographic proﬁles, unlike some
smaller studies that recruit patients from a speciﬁc region,
which might not represent the whole population. However,
some limitations exist in this study. First, the nominal
diagnosis of glaucoma and all of the comorbidities that we
assessed are all derived from ICD-9-CM diagnosis codes and
may be less accurate than diagnoses obtained through a
standard procedure. Second, some other potential confounding
factors, which could have contributed to zolpidem use and/or
glaucoma risk, such as socioeconomic status,21 educational
background, emotional handicap,22–24 and glaucoma family
history,24 are not available in our database, which might
bias the current work. In one recent study in Canada,21 the
authors provided evidence that socioeconomic deprivation is
associated with greater severity of glaucoma at presentation
than those not experiencing socioeconomic deprivation.
Glaucoma has been noted to be associated with anxiety,
depression, and type-A personality,22,23 and family history of
the disease is also a well-known risk factor.24 All of these
risk factors merit consideration in future research. Third,
causality could not be established from this population-based
observational longitudinal study because we could not verify
the exact temporal relationship between zolpidem use and
glaucoma from the database. Fourth, the glaucoma incidence
from this database is approximately 0.15% based on the ICD-
9 coding 365.xxx, which resulted in a relatively small sample
size. To date, there has been no large-scale glaucoma survey
in Taiwan. Consequently, the validity of the current database
is hard to evaluate without reference data. Furthermore, our
current work is the ﬁrst study to evaluate the relationship
between zolpidem use and onset of glaucoma. We do not have
any former studies with which to compare our ﬁndings.
In conclusion, this population-based case-control study
revealed that zolpidem use was associated with a signiﬁcantly
increased risk of glaucoma. In light of the widespread
prescription of zolpidem and increasing prevalence of
glaucoma, all practicing physicians should bear in mind that
glaucoma risk in insomnia patients might increase while
taking zolpidem. Further larger conﬁrmatory studies are
warranted to clarify this important issue.
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